Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Pharmaceutical firms face more flak in India for allegedly flouting pricing norms – this time more than 200 formulations were allegedly launched in the country without seeking price approvals, though some companies claim they are fully compliant with the norms.
Dr Reddy’s Laboratories hopes GE Healthcare’s FlexFactory biomanufacturing platform can deliver multiple operational gains, including a potentially more fail-safe compliance system at its site. The Indian company expects to roll out its first biosimilar MAb from the new set-up next year.
Eli Lilly and Lupin are building on their alliance in India, with Lupin introducing Lilly’s Cialis (tadalafil) – a teeming market awaits the product, however.
India appears to be on course to developing a national rare disease policy, with the adoption of a specific definition for rare diseases and the initiation of a rare disease registry in the country.
Glenmark Pharmaceuticals reported overall growth in the fourth quarter of 2016-17, but investors bludgeoned the company’s shares on concerns around the slow traction of generic Zetia in the US and a sharp decline in earnings on a sequential basis.
Thailand’s Siam Bioscience is developing a basket of biosimilars and has plans to establish a European beachhead for the launch of some products, starting with pegfilgrastim.